Research To Practice | Oncology Videos

Latest Episodes:

Chronic Myeloid Leukemia | Meet The Professor: Optimizing the Management of Chronic Myeloid Leukemia — Part 1 Jul 20, 2022

Show notes

Featuring perspectives from Dr Jorge Cortes, including the following topics:

Introduction: Journal Club with Dr Cortes (0:00)
Case: A man in his early 40s with chronic myeloid leukemia (CML) and osteopenia after long-term imatinib therapy — Rajalaxmi McKenna, MD (15:00)
Case: A man in his early 60s with chronic phase CML (CP-CML) and continued detectable BCR-ABL transcript on bosutinib — Bruce Bank, MD (23:55)
Case: A man in his early 70s with CP-CML and notable toxicities from several BCR-ABL tyrosine kinase inhibitors (TKIs) — Gigi Chen, MD (27:37)
Case: A woman in her late 40s with CML in complete molecular response for more than 3 years with nilotinib — Michael R Grunwald, MD (36:05)
Case: A woman in her mid 60s with CP-CML and negative BCR-ABL mutational analyses who experiences lack of disease response to several BCR-ABL TKIs — Shams Bufalino, MD (43:27)
Case: A man in his early 40s with CP-CML who is found to have a T315I mutation — Dr Grunwald (44:45)
Appendix of Key Recent Data Sets (53:26)

CME information and select publications

Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 1 Jul 19, 2022

Show notes

Featuring perspectives from Dr Joel Neal, including the following topics:

Introduction: Journal Club with Joel W Neal, MD, PhD (0:00)
Case: A woman in her mid 60s with Stage I NSCLC with an EGFR mutation and emphysema — Joanna Metzner-Sadurski, MD (18:00)
Case: A woman in her late 60s with localized papillary NSCLC with an EGFR L864Q mutation — William R Mitchell, MD (20:42)
Case: A woman in her early 70s with Stage IIIA NSCLC and EGFR L858R, ROS1 and TP53 mutations — Neil Morganstein, MD (37:25)
Case: A woman in her early 50s with metastatic NSCLC with an EGFR exon 20 insertion (PD-L1 TPS 20%) — Julia Saylors, MD (43:11)
Case: A woman in her early 70s with metastatic NSCLC with an EGFR exon 19 mutation (PD-L1 TPS 50%) — Namrata I Peswani, MD (53:53)

CME information and select publications

Breast Cancer | Oncology Today with Dr Neil Love: Key Presentations on Breast Cancer from the 2022 ASCO Annual Meeting (Companion Faculty Lecture) Jul 18, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Angela DeMichele, including the following topics:

HER2 and HER3-directed therapies for locally advanced and metastatic breast cancer (0:00)

Immunotherapies and antibody-drug conjugates for triple-negative breast cancer and genetic alterations associated with response (13:14)

Targeted therapies for estrogen receptor-positive, HER2-negative breast cancer; Response rates by molecular subtypes (25:34)

CME information and select publications

Breast Cancer | Oncology Today with Dr Neil Love: Key Presentations on Breast Cancer from the 2022 ASCO Annual Meeting Jul 18, 2022

Show notes

Featuring an interview with Dr Angela DeMichele, including the following topics:

Staining for HER2 expression and clinical relevance of HER2-0 breast cancer (0:00)
Biology of HER2-mutated breast cancer; sequencing of sacituzumab govitecan and trastuzumab deruxtecan for estrogen receptor (ER)-negative breast cancer (4:21)
Role of trastuzumab deruxtecan in HER2-low, ER-positive breast cancer; biologic rationale for targeting HER3 with patritumab deruxtecan (11:39)
Ongoing clinical trials of tucatinib for HER2-positive locally advanced or metastatic breast cancer: HER2CLIMB-04 and HER2CLIMB-05 (17:16)
Recent data with and biomarkers of response for sacituzumab govitecan for triple-negative breast cancer (TNBC); benefits of chemotherapy for disease with a BRCA mutation (22:22)
Molecular alterations associated with PARP inhibitor response and potential implications for clinical practice (25:45)
Current role of PARP inhibitors, immunotherapy, chemotherapy, and combination therapies for TNBC (28:57)
Potential role of sacituzumab govitecan for ER-positive, HER2-negative breast cancer (33:54)
Tolerability of capivasertib; using genomic testing to identify tumor subtypes less responsive to endocrine therapy (37:24)
Using genomic risk scores to inform treatment for ER-positive, HER2-negative breast cancer that has spread to lymph nodes (43:04)

CME information and select publications

Chronic Lymphocytic Leukemia | Meet The Professor: Current and Future Management of Chronic Lymphocytic Leukemia — Part 6 Jul 15, 2022

Show notes

Featuring perspectives from Dr Jeff Sharman, including the following topics:

Introduction (0:00)
Case: A man in his late 50s with progressive small lymphocytic lymphoma who developed acalabrutinib-associated rash — Shams Bufalino, MD (22:14)
Case: A man in his late 60s with recurrent deep-vein thrombosis who is receiving warfarin and is diagnosed with chronic lymphocytic leukemia (CLL) requiring treatment — Shaachi Gupta, MD, MPH (27:27)
Case: A man in his early 70s with IGHV-unmutated CLL who has severe cardiac disease requiring a defibrillator — Rajalaxmi McKenna, MD (34:45)
Case: A man in his early 70s with CLL who remains in remission after treatment with chlorambucil/obinutuzumab — Philip L Brooks, MD (40:43)
Case: A man in his early 50s with IGHV-unmutated CLL and del(17p) who developed atrial fibrillation on ibrutinib — Vignesh Narayanan, MD (45:03)
Case: A woman in her late 80s with CLL transformed to Hodgkin lymphoma — Spencer H Bachow, MD (51:46)
Case: A man in his late 50s with relapsed IGHV-mutated CLL who experienced acalabrutinib-associated headache — Erik Rupard, MD (56:22)
Case: A woman in her mid 60s with IGHV-unmutated CLL and hemolytic anemia — Joanna Metzner-Sadurski, MD (1:01:38)

CME information and select publications

Prostate Cancer | Fred Saad, MD Jul 14, 2022

Show notes

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 2: Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combination Strategies — Dr Fred Saad

CME information and select publications

Prostate Cancer | Johann S de Bono, MB ChB, MSc, PhD, FMedSci Jul 14, 2022

Show notes

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 1: Optimal Integration of PARP Inhibitor Monotherapy into the Management of Metastatic Castration-Resistant Prostate Cancer — Prof Johann de Bono

CME information and select publications

Prostate Cancer | PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed Jul 14, 2022

Show notes

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 Jul 13, 2022

Show notes

Featuring perspectives from Dr Shannon Westin, including the following topics:

Introduction (0:00)
Case: A woman in her late 50s with Stage IIIC high-grade serous carcinoma with a gBRCA2 mutation — Gigi Chen, MD (19:58)
Case: A woman in her mid 60s with Stage IIA BRCA1/2 wild-type, high-grade serous ovarian adenocarcinoma — Syed M Ahmed, MD, PhD (23:16)
Case: A woman in her early 60s with metastatic MSS ovarian carcinoma with a gBRCA1 mutation — Syed Farhan Zafar, MD (30:14)
Case: A woman in her early 60s with multiregimen-recurrent advanced ovarian cancer with a gBRCA1 mutation — Rajalaxmi McKenna, MD (39:13)
Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Dr Ahmed (56:54)

CME information and select publications

Non-Small Cell Lung Cancer | Meet The Professor: Non-Small Cell Lung Cancer with an Actionable Target Beyond EGFR — Part 3 Jul 12, 2022

Show notes

Featuring perspectives from Dr Melissa Johnson, including the following topics:

Introduction: KRAS in Lung Cancer (0:00)
Case: A woman in her early 60s with adenocarcinoma of the lung and a ROS1 fusion, with bone, brain and leptomeningeal metastases — Gigi Chen, MD (15:52)
Case: A man in his late 50s with Stage IVa lung cancer and malignant pleural effusion and a BRAF V600E mutation (PD-L1 60%) — Jiaxin (Jason) Niu, MD, PhD (22:28)
Case: A woman in her mid 60s with adenocarcinoma of the lung, a solitary brain metastasis and an ALK fusion — Neil Morganstein, MD (29:33)
Case: A woman in her early 50s with metastatic adenocarcinoma of the lung and a RET mutation (PD-L1 TPS 40%) — Rao Mushtaq, MD (36:42)
Case: A woman in her early 70s with Stage IV lung adenocarcinoma and malignant pleural effusion and NRG1 fusion — Dr Niu (41:45)
Case: A man in his late 60s with metastatic squamous cell carcinoma of the lung with an IDH1 mutation — Sulfi Ibrahim, MD (51:08)
MET Exon 14 and HER2 Mutations (54:07)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected